Royalty Pharma Plc stock is traded at $67.57, with a volume of 4,900,538. It is up +0.01% in the last 24 hours and up +19.26% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Previous Close:
$67.56
Open:
$68.00
24h Volume:
4,900,538
Relative Volume:
1.40
Market Cap:
$30.09B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
35.39
EPS:
$1.91
Net Cash Flow:
$574.14M
1W Performance:
+2.49%
1M Performance:
+19.26%
6M Performance:
+33.96%
1Y Performance:
+67.17%
1-Day Range:
$67.51$69.77
1-Week Range:
$64.84$69.77
52-Week Range:
$36.03$69.77
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma PlcSector
HealthcareIndustry
BiotechnologyPhone
(212) 883-0200Address
110 EAST 59TH STREET, NEW YORK, NY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS